Evidence map›Paper›PMID 41954337›Full record

Observational studyCancer2026

Treatment and outcomes of pulmonary mucosa-associated lymphoid tissue lymphoma: A multicenter analysis of 186 patients.

Kazutaka Suzuki, Kana Miyazaki, Naoko Asano, Hiroyuki Takahashi, Yusuke Koba, Nobuhiro Hiramoto, Ilseung Choi, Hiroshi Arima, Toshiki Uchida, Nobuhiko Nakamura and 12 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Kazutaka SuzukiDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan.ORCID https://orcid.org/0009-0007-0225-5049
Kana MiyazakiDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan.ORCID https://orcid.org/0000-0001-6547-3181
Naoko AsanoDepartment of Molecular Diagnostics, Nagano Prefectural Shinshu Medical Center, Suzaka, Japan.
Hiroyuki TakahashiDepartment of Hematology and Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Yusuke KobaDepartment of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Nobuhiro HiramotoDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
Ilseung ChoiDepartment of Hematology and Cell Therapy, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-8920-7045
Hiroshi ArimaDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Toshiki UchidaDepartment of Hematology and Oncology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
Nobuhiko NakamuraDepartment of Hematology and Infectious Disease, Gifu University Hospital, Gifu, Japan.ORCID https://orcid.org/0000-0003-1682-7777
Hiro TatetsuDepartment of Hematology, Rheumatology, and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Fukuoka, Japan.
Hideki UryuDivision of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan.
Shunsuke ItoDepartment of Hematology, Shimane University Hospital, Izumo, Japan.
Takeharu KatoDepartment of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
Hirokazu SasakiDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Tohru MurayamaDepartment of Hematology, Hyogo Cancer Center, Akashi, Japan.
Junji HiragaDepartment of Hematology, Toyota Kosei Hospital, Toyota, Japan.
Naoki TakahashiDepartment of Hematology, International Medical Center, Saitama Medical University, Saitama, Japan.
Tetsu KobayashiDepartment of Pulmonary and Critical Care Medicine, Mie University Graduate School of Medicine, Tsu, Japan.
Motoshi TakaoDepartment of Thoracic and Cardiovascular Surgery, Mie University Graduate School of Medicine, Tsu, Japan.
Isao TawaraDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan.
Motoko YamaguchiDepartment of Hematological Malignancies, Mie University Graduate School of Medicine, Tsu, Japan.ORCID https://orcid.org/0000-0002-7094-6489

Funding

Japanese Society of Hematology 22138Japanese Society of Hematology 23133Japan Society for the Promotion of Science 24K11513
6 · The paper itself

Abstract

backgroundExtranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with pulmonary involvement is a rare, indolent lymphoma with no standard treatment approaches.

methodsTo clarify patient characteristics, treatment, and prognosis of pulmonary MALT lymphoma in the modern era, a multi-institutional observational study of patients diagnosed between 2013 and 2022 was conducted. A modified Ann Arbor system was used for the analysis.

resultsAmong 186 eligible patients, 131 (70%) had stage IE/IIE disease, whereas 55 (30%) had stage IV disease. No patient had stage III disease. With a median follow-up of 57 months, the 4-year overall survival (OS) rates for the stage IE, IIE, and IV groups were 96%, 92%, and 90%, respectively. The stage IIE and IV groups had similar progression-free survival (PFS) that was significantly worse than that of the stage IE group (p < .001). In stage IE/IIE patients, no differences were found in OS (p = .89) or PFS (p = .90) among the first-line treatment groups. In stage IV patients, the stomach was the most common synchronous extranodal site of involvement (36%). There were no differences in OS among the first-line treatment groups (p = .64).

conclusionsThe OS of patients with MALT lymphoma with pulmonary involvement was favorable regardless of first-line treatment modality, including watchful waiting. The short PFS in the stage IIE and IV groups indicates that these groups are candidates for therapeutic development.

Indexed as

Lung NeoplasmsLymphoma, B-Cell, Marginal ZoneAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisProgression-Free SurvivalRetrospective StudiesSurvival RateTreatment Outcomeclinical coursefirst‐line treatmentprognostic factorspulmonary mucosa‐associated lymphoid tissue lymphomaretrospective multi‐institutional study

Identifiers

PMID41954337
PMCPMC13064424

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.